Alomide — Competitive Intelligence Brief

Alomide (LODOXAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mast Cell Stabilizer. Area: Rare Disease.

marketed Mast Cell Stabilizer G-protein coupled receptor 35 Rare Disease Small molecule

Target snapshot

Alomide (LODOXAMIDE) — Novartis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alomide TARGET	LODOXAMIDE	Novartis	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1993-01-01
Alocril	NEDOCROMIL	AbbVie	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1992-01-01
Intal	cromoglicic acid	Pfizer	marketed	Mast Cell Stabilizer	G-protein coupled receptor 35	1982-01-01
Lasix	furosemide	Generic (originally Hoechst AG)	marketed	Loop Diuretic [EPC]	ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35	1966-07-01
Frusemide	Frusemide	Melbourne Health	marketed		ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35
Cromoglycate	Cromoglycate	Vishwajit Nimgaonkar, MD PhD	phase 3		Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20
CROMOLYN SODIUM	CROMOLYN SODIUM		marketed	Mast cell stabilizer	Mast cells	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2034-04-03 — Lasix · 11433044 · Method of Use · US
• 2034-04-03 — Lasix · 9884039 · Method of Use · US
• 2034-04-03 — Lasix · 12370168 · Formulation · US
• 2034-04-03 — Lasix · 10272064 · Formulation · US

Sponsor landscape (Mast Cell Stabilizer class)

1. AbbVie · 1 drug in this class
2. Novartis · 1 drug in this class
3. Pfizer · 1 drug in this class